15 results about "Haptoglobin" patented technology

A milking arrangement comprising a milking machine for milking an animal, wherein the milking arrangement comprises a control unit that is configured to obtain identity of the animal in connection with milking of the animal, obtain a reference point in time of a lactation cycle of the identified animal, determine to take at least one milk sample of the animal, when a predetermined time period has passed from the reference point in time; obtain a Haptoglobin level from the milk sample, compare the obtained Haptoglobin level with a Haptoglobin reference limit, and indicate health condition of the animal, based on the made comparison.

The present invention relates to in vitro methods for aiding in the detection of hepatocellular carcinoma (HCC) in a subject. The method may comprise determining the amount of one or more N-glycan structure attached to haptoglobin (i.e. of the β-chain of haptoglobin having the sequence given in SEQ ID NO: 1) in a sample obtained from said subject and comparing the amount of said one or more glycan structure to a reference amount of said one or more glycan structure, wherein an altered amount of said one or more glycan structure in said patient sample relative to the reference amount of said one or more glycan structure is indicative for HCC. Further, the present invention relates to the use of one or more glycan structure attached to haptoglobinor of a glycopeptide derived from haptoglobin in combination with AFP and / or PIVKA-II in the detection of HCC.

The invention provides a method of detecting renal cancer mark- ers in a biological sample from a patient suspected of or to be evaluated for having renal cancer, comprising detecting one or more marker proteins selected from Lipocalin 15, Serum amyloid A1, and Haptoglobin, in the biological sample. The invention further provides a kit suitable for use with the inventive method.

The present invention relates to haptoglobin (Hp), and optionally hemopexin (Hx), for use in the treatment of traumatic brain injury (TBI) and in particular in the treatment or prevention of a secondary brain injury in a subject suffering from a TBI.

The present invention relates to in vitro methods for aiding in the detection of hepatocellular carcinoma (HCC) in a subject comprising determining the amount of one or more glycan structure at position N207 of haptoglobin (i.e. of the ß-chain of haptoglobin having the sequence given in SEQ ID NO: 1) in a sample obtained from said subject. Also disclosed are a glycan structure as well as a glycopeptide comprising said glycan structure, both of great utility in the detection of HCC. Further, the present invention relates to the use of one or more glycan structure at position N207 or of a glycopeptide comprising N207 of haptoglobin in combination with AFP and / or PIVKA in the detection of HCC.

A system and method for in-situ quantitative assessment of Bovine Mastitis (BM) in collected milk samples using optical imaging is disclosed. A bio-functionalized assay tray contains multiple wells, each having a gel with a specially prepared mixture of hemoglobin (Hb) and metal ions. At least one of the wells is filled with a reference milk sample which is characteristic of milk with no BM disease. Other wells are filled with collected milk samples. After waiting an interaction time, luminol and hydrogen peroxide solutions are added to the wells, causing chemiluminescent (CL) light emission. The intensity of CL light emitted by wells containing haptoglobin (Hp) is inhibited due to Hb-Hp binding. After waiting a CL light stabilization time, the tray is placed in a dark box, and a camera and image processor are used to analyze the CL light intensities. A calibration curve yields the Hp concentration in each well.

The application discloses a monoclonal antibody of feline haptoglobin and application thereof, and the monoclonal antibody of feline haptoglobin or an antigen binding fragment thereof, and the monoclonal antibody of feline haptoglobin or the antigen binding fragment thereof comprises Hp-mAb8, Hp-mAb9 and / or Hp-mAb10, the amino acid sequences of CDR1, CDR2 and CDR3 of the heavy chain of the monoclonal antibody Hp-mAb8 are GFSLDGYD, IYVSDVT and ARDSDVGVSGYTFPDI respectively, and the amino acid sequences of CDR1, CDR2 and CDR3 of the light chain of the monoclonal antibody Hp-mAb8 are ESISTNR, PAS and QSGYATADVPNT respectively. The monoclonal antibody of feline haptoglobin has wider detection linearity, reduced cost, and can meet the budget of most cat-keeping families.

The present invention relates to haptoglobin (Hp), and optionally hemopexin (Hx), for use in the treatment of traumatic brain injury (TBI) and in particular in the treatment or prevention of a secondary brain injury in a subject suffering from a TBI.

A method for immunological detection of hemoglobin, the method comprising a step for performing immunological detection using an anti-hemoglobin antibody in the presence of hemoglobin and haptoglobin, the haptoglobin having the following characteristics (1): (1) at least a portion of an N-linked sugar chain is deleted. The present invention further provides a method for suppressing fluctuations in the detection value of hemoglobin, a method and a solution for stabilizing hemoglobin, a kit for detecting hemoglobin, and the haptoglobin and a method for producing the haptoglobin. According to the present invention, it is possible to detect hemoglobin by suppressing fluctuations in the detection value of hemoglobin due to haptoglobin.

An immunological measurement method for hemoglobin, comprising a step of performing the immunological measurement using an anti-hemoglobin antibody under coexistence of the hemoglobin and haptoglobin, the haptoglobin having a characteristic (1) below: (1) at least a portion of an N-linked glycan is deleted. The present invention further provides a method for suppressing change in measurement values of hemoglobin, a method and a solution for stabilizing hemoglobin, a hemoglobin measurement kit, and the haptoglobin and a method for producing the same. According to the present invention, hemoglobin can be measured while suppressing haptoglobin-associated change in hemoglobin measurement values.

Provided herein are compositions for increasing apolipoprotein L1 (ApoL1) in a target cell. The ApoL1 may be a recombinant protein or an endogenous protein, optionally in a complex comprising ApoL1. Provided herein are antibodies and other binding molecules that specifically bind to apolipoprotein L1 (ApoL1) and haptoglobin associated protein (Hpr). In preferred embodiments, the antibodies and other molecules preferably bind to an ApoL1-containing complex, such as a trypanosomal cleavage factor (TLF), under physiological conditions. In preferred embodiments, the antibodies and antigen binding fragments are bispecific, trispecific, and multispecific molecules, which can bind to the ApoL1-containing complex and further bind to a cell specific antigen. Also provided are methods of using such molecules to increase flow of an ApoL1-containing complex into a target cell expressing the cell-specific antigen. Such an increase in ApoL-containing complexes may increase cell death. In a preferred embodiment, the target cell is a cancer cell, such as a blood cancer cell or a solid tumor cell.

The invention provides a double qPCR method, a reagent and a kit for realizing ultra-early diagnosis of African swine fever by jointly detecting nucleic acids of host biomarkers HP and ASFV. According to the present invention, the HP and B646L genes are adopted to establish the dual fluorescence PCR method, the biomarker HP and ASFV nucleic acid detection are innovatively combined for use, the ASFV infection is diagnosed, the potential ASFV early stage infected pigs in the pig farm can be screened, the diagnosis blank period before the occurrence of the viremia after the ASFV infection is filled, and the kit can be used for the diagnosis of the ASFV early stage. Especially, a new technical tool is provided for coping with challenges of African swine fever virus variation and recombinant strains. According to the method, the efficiency of biological safety measures can be improved, the implementation precision of a'detection-killing 'strategy is optimized, the method is suitable for precise removal when ASF epidemic outbreak occurs in a pig farm or ASF epidemic outbreak occurs in the periphery, and an early monitoring and early warning means is provided for epidemic prevention and control.

The present invention addresses the problem of providing, for example, an evaluation method with which highly reliable information about the condition of inflammation after parturition can be provided before parturition. In the present embodiment, the condition of inflammation in a ruminant after parturition is evaluated using at least one value from among: concentration values of 25 kinds of amino acids (Ala, Arg, Asn, Asp, BCAA, Cit, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, 3MeHis, Orn, Phe, Pro, Ser, Tau, Thr, Trp, Tyr, Val) in the blood of the ruminant before parturition; test values of 37 biochemical components (ALB, ALT, AST, BHBA, BUN, Ca, gGTP, Glc, Glob, NEFA, T-Bil, TCHO, TG, TP, P, Na, K, Cl, GGT, ALP, LDH, CPK, LDL-C, HDL-C, Mg, AMY, PA, LA, CRE, LBP, IL-1β, haptoglobin, serum amyloid A, IL-6, TNF-α, cortisol, kynurenine) in the blood; and measurement values (d-ROMs value, BAP value, BAP value / d-ROMs value, and d-ROMs value / BAP value) of four measurement items obtained from the blood.

The present disclosure relates generally to methods of treating or preventing an adverse secondary neurological outcome in a subject following a haemorrhagic stroke accompanied by extravascular erythrolysis and release of cell-free heme and / or cell-free haemoglobin (Hb) into a cerebral spinal fluid (CSF), the method comprising exposing the CSF of a subject in need thereof to a therapeutically effective amount of hemopexin (Hx) and for a period of time sufficient to allow the Hx to form a complex with, and thereby neutralise, the cell-free heme and, optionally, exposing the CSF of the subject to a therapeutically effective amount of haptoglobin (Hp) and for a period of time sufficient to allow the Hp to form a complex with, and thereby neutralise, the cell-free Hb.

Provided herein are compositions and methods for the treatment of hemolysis in pulmonary tissue. Also provided herein are methods of purifying proteins including apo-transferrin, haptoglobin, hemopexin, and combinations thereof.